



# Pharma Finance 2007

## ROMA - ITALY - MAY 10-11

# 5TH ANNUAL PARTNERING CONFERENCE

### Market Data (AS OF MAY 1, 2007)



Symbol	ANX
Exchange	AMEX
Current Price	\$2.44
Shares Outstanding	89.68M
Market Capital	\$218.8M
52wk RANGE	\$1.90-\$5.38
Average Volume	471,159
YTD % Change	-49.90%

### COMPANY FACT SHEET



**ADVENTRX**  
PHARMACEUTICALS

### FINANCIAL HIGHLIGHTS (YEAR ENDING DEC 31ST, 2006)

<b>Net Revenue:</b>	<b>N/A</b>	<b>Earnings per Share:</b>	<b>(0.40)</b>
<b>Net Income:</b>	<b>(29.33M)</b>	<b>Weighted Average:</b>	<b>74M</b>

### CONFERENCE OBJECTIVES

**Partnering and licensing deals in European market, with Larger Pharmaceutical Distributors.**

### RECENT DEVELOPMENTS

**April 5, 2007**

ADVENTRX Grants Manufacturing Contract for ANX-514 (Docetaxel Emulsion)

**March 26, 2007**

ADVENTRX and TRx Pharma Announce Zanaflu® Registered as the Brand Name for ANX-211 (Chitosan Gel)

**March 20, 2007**

ADVENTRX Awards Manufacturing Contract for ANX-201 (Thiovir™)

### PRODUCT AND PRODUCT CANDIDATE PIPELINE

#### LEAD PROGRAMS

**ANX-510, or CoFactor®**

A biomodulator of 5-fluorouracil (5-FU), a widely used chemotherapy drug. CoFactor is in Phase 3 and Phase 2b clinical trials for the treatment of metastatic colorectal cancer, as well as in a Phase 2 clinical trial for the treatment of advanced breast cancer.

**ANX-530, or Vinorelbine emulsion**

Novel emulsion formulation of vinorelbine tartrate that is designed to reduce vein irritation associated with IV-delivery of the drug. ANX-530 is currently being tested in a 28-patient marketing enabling clinical trial for the treatment of non-small cell lung cancer.

**ANX-211, or Chitosan gel**

An intranasal/topical antiviral. U.S. rights to ANX-211 licensed to TRx Pharma, LLC, in October 2006. ADVENTRX anticipates TRx Pharma

will launch a licensed product during the 2007/2008 cold and influenza season.

**ANX-201, or Thiovir™**

A broad spectrum antiviral and reverse transcriptase inhibitor designed to be used as a novel component of highly active antiretroviral therapy (HAART) for HIV/AIDS. ADVENTRX currently plans to file an IND for a Phase 1/2 clinical trial in HIV in the first half of 2007.

**ANX-514, or Docetaxel emulsion**

A novel emulsion formulation of the anticancer drug docetaxel (Taxotere®). ANX-514 is designed to eliminate the need for multiday immunosuppressant premedication, which is recommended for Taxotere therapy to reduce the incidence and severity of hypersensitivity reactions. ADVENTRX currently plans to seek a 505(b)(2) regulatory path for ANX-514.

### ADVENTRX Pharmaceuticals

6725 Mesa Ridge Rd  
Suite 100  
San Diego, CA 92121  
(858) 552-0866  
[www.adventrx.com](http://www.adventrx.com)



**Evan Levine**  
Chief Executive Officer

### Company Description

ADVENTRX Pharmaceuticals, Inc. is a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases. The Company seeks to improve the performance and safety of existing treatments by addressing significant problems, such as drug metabolism, bioavailability, excessive toxicity and treatment resistance.